• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents.新型抗精神病药物致药物诱导运动障碍的风险。
Tremor Other Hyperkinet Mov (N Y). 2022 Jun 8;12:19. doi: 10.5334/tohm.695. eCollection 2022.
2
Long-acting injectable antipsychotics in the elderly: guidelines for effective use.老年患者长效注射用抗精神病药物:有效使用指南
Drugs Aging. 2003;20(15):1099-110. doi: 10.2165/00002512-200320150-00003.
3
Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.第二代抗精神病长效注射治疗相关的不良反应:全面系统评价。
Pharmacotherapy. 2013 Oct;33(10):1087-106. doi: 10.1002/phar.1313. Epub 2013 Jun 17.
4
Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.长效注射用帕利哌酮棕榈酸酯:疗效与安全性综述
Psychopharmacol Bull. 2017 May 15;47(2):42-52.
5
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.抗精神病药所致多巴胺超敏性精神病:药理学、标准和治疗。
Psychother Psychosom. 2017;86(4):189-219. doi: 10.1159/000477313. Epub 2017 Jun 24.
6
Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.抗精神病药物引起的运动障碍:CATIE 精神分裂症试验的启示。
Neurol Clin. 2011 Feb;29(1):127-48, viii. doi: 10.1016/j.ncl.2010.10.002.
7
8
The Extrapyramidal Symptom Rating Scale and Its Abbreviated Version: A Critical Review of Clinimetric Properties.锥体外系症状评定量表及其简表:计量学特性的批判性评价。
Psychother Psychosom. 2023;92(6):359-366. doi: 10.1159/000535113. Epub 2023 Dec 7.
9
Oral and Palmitate Paliperidone Long-Acting Injectable Formulations' Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP).棕榈酸帕利哌酮长效注射制剂在精神分裂症谱系障碍中的应用:首发精神病干预计划(CRUPEP)的回顾性队列研究。
Int J Neuropsychopharmacol. 2021 Sep 21;24(9):694-702. doi: 10.1093/ijnp/pyab021.
10
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].[精神分裂症患者护理环境的成本效益分析:长效注射制剂下非典型抗精神病药物的影响]
Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5.

引用本文的文献

1
Clinical prediction of sodium valproate-induced movement disorders in hospitalized patients: a nomogram-based model using real-world data.住院患者丙戊酸钠所致运动障碍的临床预测:基于列线图的真实世界数据模型
Int J Clin Pharm. 2025 Aug 19. doi: 10.1007/s11096-025-01984-2.
2
Long-Acting Injectable Antipsychotic Use and Discontinuation Rates in Children and Adolescents With Schizophrenia Using Medicaid Claims Data.利用医疗补助索赔数据研究精神分裂症儿童和青少年长效注射用抗精神病药物的使用及停药率
Early Interv Psychiatry. 2025 Jun;19(6):e70063. doi: 10.1111/eip.70063.
3
Real-World Data Mining for Signal Detection of Antipsychotics-Associated Adverse Events Using the Korea Adverse Event Reporting System (KAERS) Database.利用韩国不良事件报告系统(KAERS)数据库进行抗精神病药相关不良事件信号检测的真实世界数据挖掘。
Medicina (Kaunas). 2024 Oct 18;60(10):1714. doi: 10.3390/medicina60101714.
4
A Systematic Review of Oral Vertical Dyskinesia ("Rabbit" Syndrome).口腔垂直运动障碍(“兔子”综合征)的系统评价。
Medicina (Kaunas). 2024 Aug 19;60(8):1347. doi: 10.3390/medicina60081347.

本文引用的文献

1
Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis.32 种口服和长效注射抗精神病药治疗成人精神分裂症维持治疗的疗效和耐受性比较:系统评价和网络荟萃分析。
Lancet. 2022 Feb 26;399(10327):824-836. doi: 10.1016/S0140-6736(21)01997-8.
2
Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study).新型部分D3/D2激动剂卡立普嗪对以阴性症状为主的精神分裂症患者的早期临床疗效(开放标签、非对照研究)
Front Psychiatry. 2022 Jan 24;12:770592. doi: 10.3389/fpsyt.2021.770592. eCollection 2021.
3
Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.乌洛托品:一种用于治疗精神分裂症的TAAR1激动剂。
ACS Med Chem Lett. 2021 Dec 6;13(1):92-98. doi: 10.1021/acsmedchemlett.1c00527. eCollection 2022 Jan 13.
4
Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.奥氮平/氨苯砜:一种用于治疗双相 I 型障碍和精神分裂症的新药获得批准。
Ann Pharmacother. 2022 Sep;56(9):1049-1057. doi: 10.1177/10600280211070330. Epub 2022 Jan 18.
5
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.匹莫范色林用于治疗精神分裂症阴性症状:北美和欧洲ADVANCE 2期随机、安慰剂对照试验的结果。
Lancet Psychiatry. 2022 Jan;9(1):46-58. doi: 10.1016/S2215-0366(21)00386-2. Epub 2021 Nov 30.
6
Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study.利培酮 ISM 每月注射 1 次治疗精神分裂症的 12 个月开放性扩展研究的长期疗效和安全性。
Schizophr Res. 2022 Jan;239:83-91. doi: 10.1016/j.schres.2021.11.030. Epub 2021 Nov 27.
7
New Antipsychotic Medications in the Last Decade.过去十年中的新型抗精神病药物。
Curr Psychiatry Rep. 2021 Nov 29;23(12):87. doi: 10.1007/s11920-021-01298-w.
8
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics.新型和新兴的精神分裂症治疗方法:对其药理学、疗效和相对于现有抗精神病药物的副作用特征的叙述性综述。
Neurosci Biobehav Rev. 2022 Jan;132:324-361. doi: 10.1016/j.neubiorev.2021.11.032. Epub 2021 Nov 24.
9
Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.用于治疗伴有 1 型或 2 型双相障碍的重性抑郁发作的卢美哌隆的疗效和安全性:一项 3 期随机安慰剂对照试验。
Am J Psychiatry. 2021 Dec;178(12):1098-1106. doi: 10.1176/appi.ajp.2021.20091339. Epub 2021 Sep 23.
10
Asenapine: an atypical antipsychotic with atypical formulations.阿塞那平:一种具有非典型剂型的非典型抗精神病药物。
Ther Adv Psychopharmacol. 2021 Sep 11;11:20451253211035269. doi: 10.1177/20451253211035269. eCollection 2021.

新型抗精神病药物致药物诱导运动障碍的风险。

Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents.

机构信息

Philadelphia Parkinson's Disease Research, Education and Clinical Center, Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center, Philadelphia, PA, USA.

Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.

出版信息

Tremor Other Hyperkinet Mov (N Y). 2022 Jun 8;12:19. doi: 10.5334/tohm.695. eCollection 2022.

DOI:10.5334/tohm.695
PMID:35836971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9187243/
Abstract

BACKGROUND

The last decade has seen development of numerous novel antipsychotic drugs with unique mechanisms including long-acting formulations for clinical use. A comparative assessment of these new drugs with each other and previous antipsychotics have not been performed with regards to risk for drug-induced movement disorders (DIMD).

METHODS

Medline was searched from January 2010 to February 2022 for primary research articles and review articles in English using the search terms "extrapyramidal" and "tardive" with individual drug names of novel antipsychotics.

RESULTS

We identified articles describing the risk of DIMD with 6 novel antipsychotics, 4 novel formulations, and 3 experimental antipsychotics. Both short- and long-term data generally showed comparable to lower risk of DIMD with novel antipsychotics and recent long-acting formulations compared to previously marketed antipsychotics.

DISCUSSION

Several novel antipsychotics, particularly lumateperone and pimavanserin, show promise in being able to treat psychosis while reducing the risk of DIMD. Long-acting paliperidone may reduce risk of DIMD while other long-acting injectable formulations of SGA have similar risk of DIMD compared to oral formulations. New drug targets for treating psychosis without dopamine blockade also show promise.

摘要

背景

在过去的十年中,出现了许多具有独特作用机制的新型抗精神病药物,包括用于临床的长效制剂。尚未对这些新药与其他抗精神病药物进行相互比较评估,以评估其引起药物诱导运动障碍(DIMD)的风险。

方法

使用搜索词“锥体外系”和“迟发性”以及新型抗精神病药物的个别药物名称,从 2010 年 1 月至 2022 年 2 月在 Medline 上以英文搜索了原始研究文章和综述文章。

结果

我们确定了描述 6 种新型抗精神病药物、4 种新型制剂和 3 种实验性抗精神病药物的 DIMD 风险的文章。短期和长期数据通常表明,新型抗精神病药物和最近的长效制剂与以前上市的抗精神病药物相比,DIMD 的风险相似或更低。

讨论

几种新型抗精神病药物,特别是鲁拉西酮和匹莫范色林,在治疗精神病的同时降低 DIMD 的风险方面显示出了希望。长效帕利哌酮可能会降低 DIMD 的风险,而其他长效 SGAs 注射制剂与口服制剂相比,DIMD 的风险相似。治疗精神病而不阻断多巴胺的新药物靶点也显示出了希望。